drugset
drugset / Trial / NCT00454649

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

NCT00454649 ↗

Phase 1 Completed 102 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.

Timeline

Start
2005-12
Primary completion
2009-08
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Capecitabine Small molecule 1250 mg/m2 Oral
Subject Carboplatin Small molecule — Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 80 mg/m2 Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Docetaxel Small molecule 100 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1250 mg/m2 Intravenous
Subject Paclitaxel Small molecule 90 mg/m2 Intravenous
Subject Paclitaxel Small molecule 200 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

neoplasm